StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

Equities researchers at StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

ONVO opened at $0.43 on Tuesday. The firm has a market cap of $7.40 million, a P/E ratio of -0.51 and a beta of 0.45. Organovo has a 1-year low of $0.32 and a 1-year high of $1.83. The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.45.

Organovo (NASDAQ:ONVO) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Equities analysts anticipate that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.